SecSonar.com

Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Arrowhead Pharmaceuticals, Inc. (ARWR) is a Biotechnology company based in US with a market capitalization of $10.9B. Revenue grew 23258.2% year-over-year and the company generated $156.9M in free cash flow. This page tracks ARWR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 609 employees · IPO Dec 16, 1993

Valuation

Valuation & price

$76.67 · as of May 17, 2026 · -8.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

23.29

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$83.99$49.35$14.71Jul 25Dec 25Jul 26Jul 7, 25$16.84Jul 9, 25$18.88Jul 11, 25$18.31Jul 15, 25$17.63Jul 17, 25$18.85Jul 21, 25$14.71Jul 23, 25$15.92Jul 25, 25$15.74Jul 29, 25$15.92Jul 31, 25$15.80Aug 4, 25$16.47Aug 6, 25$16.31Aug 11, 25$17.21Aug 13, 25$19.99Aug 15, 25$20.51Aug 19, 25$19.86Aug 21, 25$20.75Aug 25, 25$20.71Aug 27, 25$21.79Aug 29, 25$22.03Sep 3, 25$27.80Sep 5, 25$29.08Sep 9, 25$27.73Sep 11, 25$29.72Sep 16, 25$29.42Sep 18, 25$31.51Sep 22, 25$32.05Sep 24, 25$32.83Sep 26, 25$32.80Sep 30, 25$34.49Oct 2, 25$34.60Oct 6, 25$37.50Oct 8, 25$36.94Oct 10, 25$35.41Oct 14, 25$35.96Oct 16, 25$38.97Oct 21, 25$38.03Oct 23, 25$37.35Oct 27, 25$39.48Oct 29, 25$40.29Oct 31, 25$42.39Nov 4, 25$37.85Nov 6, 25$39.60Nov 10, 25$39.85Nov 12, 25$41.42Nov 14, 25$41.26Nov 18, 25$40.47Nov 20, 25$38.09Nov 25, 25$46.79Nov 28, 25$52.70Dec 2, 25$57.95Dec 4, 25$64.66Dec 8, 25$68.60Dec 10, 25$68.87Dec 12, 25$70.09Dec 16, 25$64.66Dec 18, 25$66.47Dec 22, 25$69.00Dec 24, 25$70.11Dec 29, 25$69.62Jan 2, 26$67.79Jan 6, 26$70.81Jan 8, 26$65.00Jan 12, 26$65.93Jan 14, 26$65.91Jan 16, 26$63.84Jan 21, 26$67.60Jan 23, 26$67.05Jan 27, 26$66.91Jan 29, 26$69.12Feb 2, 26$73.00Feb 4, 26$68.06Feb 9, 26$62.64Feb 11, 26$61.55Feb 13, 26$63.82Feb 18, 26$64.38Feb 20, 26$63.59Feb 24, 26$63.67Feb 26, 26$63.39Mar 2, 26$64.33Mar 4, 26$65.10Mar 6, 26$59.82Mar 10, 26$59.20Mar 12, 26$55.01Mar 17, 26$57.57Mar 19, 26$56.96Mar 23, 26$56.67Mar 25, 26$60.77Mar 27, 26$57.78Mar 31, 26$62.70Apr 2, 26$61.03Apr 7, 26$61.18Apr 9, 26$66.23Apr 13, 26$63.79Apr 15, 26$70.95Apr 17, 26$69.51Apr 22, 26$73.92Apr 24, 26$73.91Apr 28, 26$70.13Apr 30, 26$73.48May 4, 26$76.39May 6, 26$79.14May 8, 26$72.69May 12, 26$79.04May 14, 26$79.69May 18, 26$73.95May 20, 26$77.14May 22, 26$74.95May 28, 26$79.05Jun 1, 26$75.20Jun 3, 26$72.55Jun 5, 26$73.09Jun 9, 26$73.33Jun 11, 26$74.41Jun 15, 26$77.15Jun 17, 26$81.04Jun 22, 26$82.00Jun 24, 26$79.81Jun 26, 26$78.89Jul 2, 26$83.99
$14.7152-week range$83.99
Loading valuation history…

Fundamentals

Key fundamentals

$10.9B

Market cap

23258.2%

Revenue growth (YoY)

100.0%

Gross margin

$156.9M

Free cash flow (USD)

-$553.1M

Net debt

Net cash position

11.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$158.3KFY 2017$31.4MFY 2018$16.1MFY 2019$168.8MFY 2020$88.0MFY 2021$138.3MFY 2022$243.2MFY 2023$240.7MFY 2024$3.6MFY 2025$829.4M
$158.3K$829.4M

Free cash flow by year

2016 → 2025

FY 2016$-68.3MFY 2017$-31.9MFY 2018$-48.6MFY 2019$161.0MFY 2020$-107.8MFY 2021$147.7MFY 2022$-188.9MFY 2023$-330.6MFY 2024$-604.3MFY 2025$156.9M
-$68.3M$156.9M

Gross margin by year

2021 → 2025

FY 20210.0%FY 202295.7%FY 202394.8%FY 2024-423.7%FY 2025100.0%
0.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventDirector AppointmentJun 16, 2026Filing
  • Insider sellInsider Sell $228K · 10b5-1 PlanLu Hongbo · Director · $228.3KMay 14, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • Insider sellInsider Sell $750K · 10b5-1 PlanHamilton James C · Chief Medical Officer · $750KApr 24, 2026Filing
  • Insider sellInsider Sell $934K · 10b5-1 PlanApel Daniel Joseph · Chief Financial Officer · $934.3KApr 24, 2026Filing

Questions

Frequently asked questions

What is Arrowhead Pharmaceuticals, Inc.'s market cap?

Arrowhead Pharmaceuticals, Inc. (ARWR) has a market capitalization of $10.9B.

What is ARWR's P/E ratio?

A meaningful P/E ratio is not available for ARWR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ARWR's price-to-book (P/B) ratio?

ARWR trades at 23.29 times book value per share.

Are insiders buying ARWR stock?

SEC Form 4 filings show no open-market insider buys at Arrowhead Pharmaceuticals, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

MDGL

Madrigal Pharmaceuticals, Inc.

$11.5B

AXSM

Axsome Therapeutics, Inc.

$12B

CYTK

Cytokinetics, Incorporated

$9.5B

KRYS

Krystal Biotech, Inc.

$9.1B

IONS

Ionis Pharmaceuticals, Inc.

$12.9B

EXEL

Exelixis, Inc.

$12.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.